- Home
- TCRT vs MTNB Comparison
TCRT vs MTNB Comparison
Compare TCRT & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- MTNB
- Stock Information
- Founded
- TCRT 1998
- MTNB 2013
- Country
- TCRT United States
- MTNB United States
- Employees
- TCRT N/A
- MTNB N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- MTNB Biotechnology: Pharmaceutical Preparations
- Sector
- TCRT Health Care
- MTNB Health Care
- Exchange
- TCRT Nasdaq
- MTNB Nasdaq
- Market Cap
- TCRT 3.8M
- MTNB 3.6M
- IPO Year
- TCRT N/A
- MTNB N/A
- Fundamental
- Price
- TCRT $4.99
- MTNB $1.00
- Analyst Decision
- TCRT
- MTNB Hold
- Analyst Count
- TCRT 0
- MTNB 1
- Target Price
- TCRT N/A
- MTNB N/A
- AVG Volume (30 Days)
- TCRT 48.8K
- MTNB 354.9K
- Earning Date
- TCRT 08-13-2025
- MTNB 08-13-2025
- Dividend Yield
- TCRT N/A
- MTNB N/A
- EPS Growth
- TCRT N/A
- MTNB N/A
- EPS
- TCRT N/A
- MTNB N/A
- Revenue
- TCRT $11,000.00
- MTNB N/A
- Revenue This Year
- TCRT $5,680,500.00
- MTNB N/A
- Revenue Next Year
- TCRT N/A
- MTNB N/A
- P/E Ratio
- TCRT N/A
- MTNB N/A
- Revenue Growth
- TCRT 83.33
- MTNB N/A
- 52 Week Low
- TCRT $1.31
- MTNB $0.47
- 52 Week High
- TCRT $6.90
- MTNB $9.60
- Technical
- Relative Strength Index (RSI)
- TCRT 66.12
- MTNB 63.74
- Support Level
- TCRT $4.72
- MTNB $0.88
- Resistance Level
- TCRT $5.24
- MTNB $1.05
- Average True Range (ATR)
- TCRT 0.46
- MTNB 0.07
- MACD
- TCRT -0.02
- MTNB 0.00
- Stochastic Oscillator
- TCRT 66.89
- MTNB 86.34
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.